Cell Systems

Integrated Biosciences Joins Illumina Ventures Labs to Design Novel Therapeutics Targeting the Transcriptome

Retrieved on: 
Martedì, Maggio 28, 2024
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Genetics, Partnership, Genomics, Cell Systems, Synthetic biology, DNA, Nature, Machine learning, Science, Ageing, Dicarboxylic acid, Drug discovery, Cell, RNA, Therapy, Pharmaceutical industry

Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced they have joined Illumina Ventures Labs to integrate the company’s drug discovery engine with Illumina sequencing.

Key Points: 
  • Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced they have joined Illumina Ventures Labs to integrate the company’s drug discovery engine with Illumina sequencing.
  • This partnership provides monetary and scientific support, enabling Integrated Biosciences to discover and design new classes of small molecule therapeutics that act by shaping the transcriptomes and methylomes of cell populations.
  • “Integrated Biosciences is an outlier early-stage company that has already pioneered breakthroughs in drug discovery.
  • The partnership with Illumina Ventures will generate additional therapeutic assets and new discovery platforms that hold the promise of reshaping drug discovery.

Integrated Biosciences Partners with Project 8p Foundation to Pioneer a New Path to Groundbreaking Treatments for Chromosomal Disorders

Retrieved on: 
Martedì, Aprile 23, 2024
Biotechnology, General Health, Health, Science, Research, Nature, Publication, Machine learning, Chromosome, Partnership, Therapy, Ageing, Synthetic biology, Biology, Cell Systems, Deletion, Gene, Pharmaceutical industry

“Chromosomal disorders have traditionally been ‘too hard’ to drug due to the large number of genes affected by deletions or duplications,” said Max Wilson, Ph.D., co-founder of Integrated Biosciences.

Key Points: 
  • “Chromosomal disorders have traditionally been ‘too hard’ to drug due to the large number of genes affected by deletions or duplications,” said Max Wilson, Ph.D., co-founder of Integrated Biosciences.
  • By supplying Integrated Biosciences with unique patient-derived cell lines, translational expertise, and valuable partnership knowhow, Project 8p Foundation demonstrates its commitment to curing chromosomal disorders with novel technologies that are accessible to all.
  • The new partnership underscores a shared commitment to transforming the lives of those affected by 8p chromosomal disorders, a central goal of the Project 8p Foundation.
  • The partnership will determine how the company’s assets can be used to treat 8p and other genetic conditions.

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
Venerdì, Marzo 8, 2024
Doctor of Philosophy, Education, MD, Drug development, DNA repair, National Cancer Institute, Breast, University, RNA, Research institute, Ovarian cancer, Cell Systems, Health, Genetics, Anatomy, Biochemistry, Bangladesh Technical Education Board, Algorithm, Adolescence, Nursing, Neoplasm, Kitagawa, Faculty, Dentistry, HPV, Child, DNA, Chromatin, Therapy, SAN, National Institutes of Health, Mentorship, Chromosome instability, Doctor of Pharmacy, Structural biology, Vaccination, Cancer Research Institute, Molecular medicine, News, Laboratory, Research, University of Texas System, Cedars-Sinai Medical Center, Survivor, BRCA2, Cell, Howard Hughes Medical Institute, School, Cancer prevention, Luan, BRCA1, Patient, Teaching, Ewing sarcoma, Cancer, Public, Vaccine

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

Integrated Biosciences Announces Nature Publication Identifying New Class of Antibiotics Discovered Via Company’s AI-Powered Platform

Retrieved on: 
Mercoledì, Dicembre 20, 2023
Research, Technology, Infectious Diseases, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, MRSA, Broad Institute, Wyss Institute, Drug discovery, Multimedia, Biology, Cell Systems, Deep learning, MIT, Biomedical engineering, Ageing, Inflammation, Cancer, AI, Leibniz Association, Notifiable disease, Harvard University, Machine learning, Toxicity, Nature, Intelligence, Medicine, Therapy, Fibrosis, Synthetic biology, Pharmaceutical industry

This discovery represents one of the first new classes of antibiotics in the past 60 years and is the first discovered leveraging an AI-powered platform built around explainable deep learning.

Key Points: 
  • This discovery represents one of the first new classes of antibiotics in the past 60 years and is the first discovered leveraging an AI-powered platform built around explainable deep learning.
  • Researchers at Integrated Biosciences have discovered the first-ever class of antibiotics identified using a new and explainable artificial intelligence.
  • In their study, the researchers virtually screened more than 12 million candidate compounds to identify this new class of antibiotics.
  • The publication, “Discovery of a structural class of antibiotics with explainable deep learning,” can be accessed on the Nature website at: https://www.nature.com/articles/s41586-023-06887-8 .

Integrated Biosciences Announces Synthetic Biology Platform Enabling Control Over Aging-Associated Stress Response

Retrieved on: 
Mercoledì, Luglio 19, 2023
Biotechnology, Health Technology, Pharmaceutical, Health, Cell Systems, Biomedical engineering, Neuron, Institute for Medical Engineering and Science, University, Cell death, Optogenetics, Ageing, Light, Cancer, ISR, Multimedia, Research, MIT, Cell, Synthetic biology, Assistant, Fibrosis, Developmental Biology (journal), Publication, Machine learning, Apoptosis, University of California, Santa Barbara, Drug discovery, Virtual reality, Collateral damage, Artificial intelligence, AI, Integration, Pharmaceutical industry, Science

Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, in collaboration with researchers at the University of California Santa Barbara, today announced a drug discovery platform that enables precise control of the integrated stress response (ISR), a biological pathway that is activated by cells in response to a wide variety of pathological and aging-associated conditions.

Key Points: 
  • Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, in collaboration with researchers at the University of California Santa Barbara, today announced a drug discovery platform that enables precise control of the integrated stress response (ISR), a biological pathway that is activated by cells in response to a wide variety of pathological and aging-associated conditions.
  • View the full release here: https://www.businesswire.com/news/home/20230719278215/en/
    Integrated Biosciences has developed novel tools to manipulate the integrated stress response (ISR), a key hallmark of aging.
  • In Integrated Biosciences’ platform, neuroglioma and osteosarcoma cancer cells were genetically modified such that their ISR could respond to light.
  • “This study demonstrates an important pillar of Integrated Biosciences' platform – that the company can use synthetic biology, and in particular optogenetics, to control age-related cellular signaling pathways.

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Retrieved on: 
Martedì, Luglio 5, 2022
Efficiency, University, Nature Genetics, Patient, Modality, Severity, Research, Senior, Therapy, Ophthalmology, Hearing, AAV, TSE, Advertising, Company, Hearing loss, Industry, Sensorineural hearing loss, Global Burden of Disease Study, Cell Systems, CSO, Differentiable function, Lancet, Factor X, Regenerative medicine, Disease, Degenerative disease, Ear, Disability, Prevalence, RNA, Quality of life, OBE, VP, Technology, Gene, Glossary, Maintenance, Biology, Knowledge, Hope, Multimedia, Doctor of Philosophy, Pharmaceutical industry, Vaccine, Medical device, Astellas Pharma

An estimated 1.57 billion people globally suffer from hearing loss1, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear2.

Key Points: 
  • An estimated 1.57 billion people globally suffer from hearing loss1, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear2.
  • This degree of hearing loss significantly reduces quality of life and, with no drug treatments currently available, represents a large unmet need.
  • Combined with Astellas' capabilities for gene therapy and research of sensorineural, this providesa clear path for the development of a novel in vivo reprogramming therapy forsensorineural hearing loss."
  • Through this collaboration,we will seek to address a significant unmet need in sensorineural hearing loss.

Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into the Clinic

Retrieved on: 
Lunedì, Novembre 22, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Patient, Adenosine A1 receptor, University, Los Angeles, Brain, Hospital, Neurodegeneration, MD, University of Texas System, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Adenosine, Doctor of Philosophy, Anatomy, Manuscript, Infarction, Umbra, penumbra and antumbra, Concussion, Centers for Disease Control and Prevention, View, Administration, Astrocyte, Ischemia, Respiration (physiology), Reperfusion, University of Warwick, Traumatic brain injury, Cell Systems, CDC, Center, Department, Drug discovery, Primate, Pharmaceutical industry

The manuscript describes the results of pre-clinical studies using AST-004, Astrocytes lead drug candidate, for the treatment of stroke.

Key Points: 
  • The manuscript describes the results of pre-clinical studies using AST-004, Astrocytes lead drug candidate, for the treatment of stroke.
  • This key study in non-human primates was designed to reproduce what typically happens when human stroke patients are treated in the emergency room.
  • The results published today in Stroke show highly significant improvements across a number of metrics, with benefits beyond the current standard of care reperfusion by thrombectomy surgery.
  • The manuscript published in Stroke utilized a sophisticated non-human primate model of stroke with the study conducted by researchers from Astrocyte Pharmaceuticals and Hamamatsu Pharma Research, Inc. of Japan.